Our Science
Our Story
News
Connect
Globe Newswire
August 1, 2024
Featured article
Read More
November 19, 2024
Publications
Society for Immunotherapy of Cancer (SITC)
READ MORE
DOWNLOAD
November 5, 2024
Public Relations
Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PR
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
In The News
Endpoints News
With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies
synbiobeta
AI-Driven Cell Therapy Pioneer Outpace Bio Raises $144M in Series B Funding
GeekWire
Protein design startup Outpace lands $144M to test treatments that target solid tumors
April 7, 2024
American Association for Cancer Research (AACR)
In vitro modeling of antigen-driven exhaustion in human CAR T cells
"Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity"
1
All
May 18, 2023
Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)
American Society for Gene & Cell Therapy (ASGCT)
OutSmart™ IL-2/15: A CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity
May 11, 2023
BioCentury
Keeping up with the protein designers
May 9, 2023
Outpace Bio, a leader in protein design for cell therapy, announces presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 4, 2023
Outpace Bio, a leader in protein design for cell therapy, strengthens executive leadership team with key appointments
March 23, 2023
Outpace Bio, a leader in protein design & cell engineering, adds Bahija Jallal to Board of Directors
August 2, 2023
Seattle startups move into growing science cluster in South Lake Union
July 10, 2023
How AI is changing the way scientists engineer drugs, biosensors, enzymes and more
May 26, 2023
Outpace Bio expands cell therapy R&D, nets research collaborations in Seattle
March 31, 2021
Creating next generation smart cell therapies: Outpace Bio receives $30 million in Series A funding led by ARTIS Ventures and Lyell Immunopharma Inc
OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion
November 3, 2023
Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
October 9, 2023
Cancer Cell
Building smart CAR T cell therapies: The path to overcome current challenges
The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.